With so many different investments options, investors often have a difficult time deciding which direction is the best one for them to take.
Here at TheStreet, we attempt to declutter the plethora of information available and present it to our readers in a way so that they can make wise investment decisions.
Whether you’re an individual investor or work with a financial advisor, our objective is to help simplify the process and present information that’s user friendly.
One of today's phenomenons making a lot of noise is 3D printing.
3D printing, formally known as “additive manufacturing,” has been around since the 1980’s. Developed by inventor Chuck Hull in 1984, 3D printing is a process of producing tangible objects from a digital blueprint of a virtual 3D object. The process is accomplished by a device--a 3D printer-- that “prints” an object by layering materials on top of each other. Over the last five years, 3D printing has gone mainstream and its applications run from producing a small trinket in one’s own home to a transplantable kidney in a professional laboratory.
Who are the producers? The field is still quite raw. For the professional industries, the leaders are Stratasys (SSYS), 3D Systems (DDD), ARC Group Worldwide (ARCW), and Computer-Aided Design (CAD), all of which have experienced recent success in the stock market. For the mainstream retail consumer, private companies MakerBot and XYZprinting Inc. are the leaders, the latter of which sells 3D printers as low as $500 retail. 3D printing’s versatility makes its application enormous.
Here are nine stocks, ranked by our own proprietary quantitative ranking system at TheStreetRatings.com, that can give investors exposure to 3D printing:
Organovo Holdings Inc. (ONVO)
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs.
Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; and L'Oreal. The company was founded in 2007 and is headquartered in San Diego, CA.
Free Report: Jim Cramer's Best Stocks for 2014
TheStreet Ratings team rates ORGANOVO HOLDINGS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate ORGANOVO HOLDINGS INC (ONVO) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow."
You can view the full analysis from the report here: ONVO Ratings Report